Click here to read more Quest articles. print | Print this page
From the Spring 2016 Quest
A recent study found that the Prostate Health Index (PHI) test could help predict high-grade prostate cancer in African American men.

Researchers at Johns Hopkins assessed PHI values in 80 African- American patients with PSA values of 2-10 ng/ml prior to their radical prostatectomies. Twenty percent of the men had pathological stage 3 (pT3) prostate cancers. Although age, PSA and percentage-free PSA were similar among all the men, PHI values were significantly greater in the patients with stage 3 disease. Also, a PHI value greater than 50 was associated with increased odds of non-organ-confined cancer.

PHI is a simple blood test that is nearly 3 times more accurate in detecting prostate cancer than the free/total PSA test. Dr. Catalona led the national study that led to the approval of PHI by the U.S. Food and Drug Administration.

Adding PHI to a baseline model that included digital rectal exams (but not Gleason score or percentage of positive biopsy cores) improved the model’s diagnostic accuracy by 12.9% compared to models with other individual biomarkers, such as PSA.

African-American men tend to have more aggressive prostate cancer than Caucasian men. Although the cohort in this study is small, the findings mirror previous findings in the overall population.

 

Close this window